Skip to Main Content

Put this in the category of good problems to have: In its first four years on the market, Keytruda, made by Merck, has had the best sales launch in the history of cancer drugs.

In the third quarter of 2018, Merck reported sales of $1.9 billion of the checkpoint inhibitor, 18 percent of the company’s total revenue. Keytruda sales have now surpassed those of Opdivo, a similar medicine from Bristol-Myers Squibb. According to projections collected by Evaluate Pharma and touted by Merck, full-year sales of Keytruda will approach $7 billion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • What pains me even more is they are saying their revenue by 2020 will be like 16 billion fda released a warning to doctors in 2017 asking to stop the trials but I suppose money talks

  • Well this drug actually killed my mother caused a disease that is called myanstinious gravis and paralyzed her so yeah it does pain me to read this article

  • I am not impressed with the knowledge that your company made so much money for a drug that is supposed to help people with a serious disease as Cancer is. This drug did NOT do my son any good after 11 months but cause him alot of side effects . It’s a shame that you are able to brag about the money made from this. Unbelievable!!!

  • “To much on one drug,” Matthew? Compared to AbbVee and the former Celgene, that’s not so much of a concentration, is it? (Enjoy the rest of JPM!)

Comments are closed.